AstraZeneca PLC (NASDAQ:AZN) Position Raised by Chilton Capital Management LLC

Chilton Capital Management LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 2.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 370,832 shares of the company's stock after acquiring an additional 8,387 shares during the period. Chilton Capital Management LLC's holdings in AstraZeneca were worth $27,256,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Bank of America Corp DE grew its stake in AstraZeneca by 189.3% in the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock worth $1,574,247,000 after purchasing an additional 15,722,197 shares in the last quarter. Marshall Wace LLP acquired a new position in AstraZeneca in the fourth quarter worth about $254,018,000. Boston Partners grew its stake in AstraZeneca by 9,985.6% in the fourth quarter. Boston Partners now owns 3,707,479 shares of the company's stock worth $243,444,000 after purchasing an additional 3,670,719 shares in the last quarter. Raymond James Financial Inc. acquired a new position in AstraZeneca in the fourth quarter worth about $158,018,000. Finally, Alyeska Investment Group L.P. grew its stake in AstraZeneca by 220.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 3,027,511 shares of the company's stock worth $198,363,000 after purchasing an additional 2,083,645 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas initiated coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $85.00.

AstraZeneca Stock Performance

Shares of AZN traded up $0.80 during mid-day trading on Wednesday, reaching $70.82. 3,662,688 shares of the company's stock traded hands, compared to its average volume of 5,260,237. The business's 50-day moving average price is $70.74 and its 200-day moving average price is $70.71. The stock has a market capitalization of $219.64 billion, a P/E ratio of 28.44, a price-to-earnings-growth ratio of 1.28 and a beta of 0.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The firm had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. During the same quarter in the previous year, the company earned $2.06 earnings per share. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. Equities analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.